

***Fiscal Year 2016 Neurofibromatosis Research Program (NFRP)  
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Clinical Consortium Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• Program Announcement</li> <li>• General Application Instructions</li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b> W81XWH-16-NFRP-CCA</p>	<p>The Operations Center PI must be an independent investigator at or above the level of Associate Professor (or equivalent) with experience in developing and running large-scale initiatives such as clinical trials or consortia.</p>	<ul style="list-style-type: none"> <li>• Supports consortium that will conceive, design, develop, and conduct collaborative Phase I and II clinical evaluations of promising therapeutic agents for the management or treatment of NF1, NF2, and schwannomatosis.</li> <li>• Open to any group of institutions with a demonstrated history of collaborative NF research.</li> <li>• All applications must include letters of intent for conducting a <b>minimum of four clinical trials</b> including at least one NF1- and one NF2-focused study; two studies must be initiated within the first year of the award.</li> </ul>	<ul style="list-style-type: none"> <li>• The maximum period of performance is 4 years.</li> <li>• The maximum allowable funding for the entire period of performance is \$9,000,000 in total costs.</li> <li>• Indirect costs may be proposed in accordance with your institution's negotiated rate agreement.</li> <li>• Note that only \$5M total funding (direct and indirect costs) allocated for this award will be from the FY16 NFRP budget; the balance is contingent upon receipt of sufficient Congressional appropriations to the NFRP in FY17 and FY18.</li> </ul>	<p><b>Pre-application (Pre-Proposal):</b> June 8, 2016 5:00 p.m. Eastern time (ET)</p> <p>Invitation to Submit an Application: by June 22, 2016</p> <p><b>Application:</b> Aug 1, 2016 11:59 p.m. ET</p>
<p><b>Clinical Trial Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• Program Announcement</li> <li>• General Application Instructions</li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b> W81XWH-16-NFRP-CTA</p>	<p>Must be <i>at or above</i> the level of Assistant Professor (or equivalent).</p>	<ul style="list-style-type: none"> <li>• Supports research with the potential to have a major impact on the treatment or management of NF.</li> <li>• Funds Phase 0, I, or II clinical trials relevant to NF and/or schwannomatosis. Combinations of phases are permitted.</li> <li>• <b><i>Must support a clinical trial and may not be used for preclinical research studies.</i></b></li> </ul>	<ul style="list-style-type: none"> <li>• The maximum period of performance is 4 years.</li> <li>• The maximum allowable funding for the entire period of performance is <b>\$900,000</b> in direct costs.</li> <li>• Indirect costs may be proposed in accordance with the institution's negotiated rate agreement.</li> </ul>	<p><b>Pre-application (Letter of Intent):</b> July 18, 2016 5:00 p.m. ET</p> <p><b>Application:</b> Aug 1, 2016 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Exploration - Hypothesis Development Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• Program Announcement</li> <li>• General Application Instructions</li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b> W81XWH-16-NFRP-EHDA</p>	<p>Investigators at all academic levels (or equivalent)</p>	<ul style="list-style-type: none"> <li>• Supports the initial exploration of innovative, high-risk, high-gain concepts and potentially groundbreaking concepts in NF research.</li> <li>• <i>Preliminary and/or published data encouraged but not required.</i></li> <li>• Projects involving human subjects or human anatomical substances must be exempt under 32 CFR 219.101(b) or eligible for expedited review under 32 CFR 219.110 or 21 CFR 56.110.</li> <li>• Clinical trials not allowed.</li> </ul>	<ul style="list-style-type: none"> <li>• The maximum period of performance is <b>2</b> years.</li> <li>• The maximum allowable funding for the entire period of performance is <b>\$100,000</b> in direct costs.</li> <li>• Indirect costs may be proposed in accordance with the institution's negotiated rate agreement.</li> </ul>	<p><b>Pre-application (Letter of Intent):</b> July 18, 2016 5:00 p.m. ET</p> <p><b>Application:</b> Aug 1, 2016 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Investigator-Initiated Research Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>Program Announcement</li> <li>General Application Instructions</li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b> W81XWH-16-NFRP-IIRA</p>	<p><b>Principal Investigator (PI):</b> Must be <i>at or above</i> the level of Assistant Professor (or equivalent).</p> <p><b>Optional Qualified Collaborator:</b> Must be <i>at or above</i> the level of Assistant Professor (or equivalent) and must plan to contribute at least a 10% level of effort for each budget period for the entirety of the award.</p>	<ul style="list-style-type: none"> <li>Supports highly rigorous, high-impact research with the potential to make an important contribution to NF research and/or patient care.</li> <li><b>Preliminary and/or published data required.</b></li> <li><b>Optional Qualified Collaborator:</b> Applications that include a Qualified Collaborator who meets criteria identified in the Program Announcement/ Funding Opportunity may apply for a higher level of funding.</li> <li>Clinical trials not allowed.</li> </ul>	<ul style="list-style-type: none"> <li>The maximum period of performance is <b>3</b> years.</li> <li>The maximum allowable funding for the entire period of performance is <b>\$525,000</b> in direct costs (<b>\$575,000</b> in direct costs if requesting an Optional Qualified Collaborator).</li> <li>Indirect costs may be proposed in accordance with the institution's negotiated rate agreement.</li> </ul>	<p><b>Pre-application (Letter of Intent):</b> July 18, 2016 5:00 p.m. ET</p> <p><b>Application:</b> Aug 1, 2016 11:59 p.m. ET</p>
<p><b>New Investigator Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>Program Announcement</li> <li>General Application Instructions</li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b> W81XWH-16-NFRP-NIA</p>	<p>Must be either an independent investigator <i>at or below</i> the level of Assistant Professor (or equivalent) <i>or</i> an established independent investigator in an area other than NF <i>at or above</i> the level of Assistant Professor seeking to transition into a career in NF research.</p> <p>To be eligible, applicants may not have received more than \$300,000 in direct costs for NF research as a PI of one or more Federally funded, non-mentored peer reviewed grants.</p> <p>PI must demonstrate a commitment of at least 10% effort toward the proposed NF research project.</p>	<ul style="list-style-type: none"> <li>Supports the continued development of promising independent investigators and/or the transition of established investigators from other research fields into a career in NF research.</li> <li>Prior experience in NF research is not required.</li> <li><b>Preliminary and/or published data relevant to NF and the proposed research project is required.</b></li> <li>Clinical trials not allowed.</li> </ul>	<ul style="list-style-type: none"> <li>The maximum period of performance is <b>3</b> years.</li> <li>The maximum allowable funding for the entire period of performance is <b>\$450,000</b> in direct costs.</li> <li>Indirect costs may be proposed in accordance with the institution's negotiated rate agreement.</li> </ul>	<p><b>Pre-application (Letter of Intent):</b> July 18, 2016 5:00 p.m. ET</p> <p><b>Application:</b> Aug 1, 2016 11:59 p.m. ET</p>